Biosig Technologies (NASDAQ:STEX – Get Free Report) and Golub Capital BDC (NASDAQ:GBDC – Get Free Report) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Volatility and Risk
Biosig Technologies has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Golub Capital BDC has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
Profitability
This table compares Biosig Technologies and Golub Capital BDC’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biosig Technologies | N/A | -462.48% | -307.38% |
| Golub Capital BDC | 21.45% | 9.91% | 4.39% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biosig Technologies | 1 | 0 | 1 | 0 | 2.00 |
| Golub Capital BDC | 0 | 2 | 4 | 1 | 2.86 |
Biosig Technologies currently has a consensus price target of $4.00, suggesting a potential upside of 504.87%. Golub Capital BDC has a consensus price target of $13.90, suggesting a potential upside of 8.68%. Given Biosig Technologies’ higher possible upside, equities research analysts clearly believe Biosig Technologies is more favorable than Golub Capital BDC.
Valuation and Earnings
This table compares Biosig Technologies and Golub Capital BDC”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biosig Technologies | $40,000.00 | 1,925.37 | -$462.77 million | ($9.05) | -0.07 |
| Golub Capital BDC | $870.78 million | 3.81 | $376.65 million | $0.65 | 19.68 |
Golub Capital BDC has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Golub Capital BDC, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 42.4% of Golub Capital BDC shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 1.4% of Golub Capital BDC shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Golub Capital BDC beats Biosig Technologies on 11 of the 15 factors compared between the two stocks.
About Biosig Technologies
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
About Golub Capital BDC
Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.
Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
